Merck to acquire Cidara Therapeutics for $9.2 billion
SAN DIEGO – Merck & Co Inc (NYSE: MRK), known as MSD outside the U.S. and Canada, said on Saturday it will acquire Cidara Therapeutics Inc (Nasdaq: CDTX) in a $9.2 billion all-cash deal, bolstering its respiratory pipeline with a late-stage antiviral candidate aimed at preventing influenza. Under the terms of the agreement, Merck will…